Skip to main content
TipRanks
Go Ultimate75% OFF

Reviva Pharmaceuticals Holdings (RVPH) Stock Price & Analysis

1,273 Followers

RVPH Stock Chart & Stats

$0.30$0.02(5.63%)
At close: 4:00 PM EST
$0.3$0.4$0.5Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.28 - $0.37
52-Week Range
$0.26 - $15.42
Previous Close
$0.28
Volume
N/A
Average Volume (3M)
32.87K
Market Cap
$3.93M
Enterprise Value
-$11.21M
Total Cash (Recent Filing)
$17.46T
Total Debt (Recent Filing)
$44.39B
Price to Earnings (P/E)
―
Beta
1.70
Next Earnings
Apr 05, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Modest Leverage

Modest leverage provides some financial cushioning while the company funds clinical development. Lower debt exposure can reduce near-term balance-sheet pressure and preserve flexibility for research spending, although this benefit remains limited by continuing losses and cash use.

Multi-indication Pipeline

Coverage of CNS, inflammatory, and cardiometabolic diseases gives the company several potential therapeutic avenues rather than dependence on one disease area. This breadth can support longer-term pipeline optionality if development programs produce differentiated clinical results.

Lead Program Focus

A defined lead program gives the clinical-stage business a central development focus and a clear basis for advancing toward potential product validation. Progress in schizophrenia and related indications could also provide a foundation for evaluating subsequent pipeline opportunities.

Bears Say

No Commercial Revenue

The absence of revenue means the company has not yet demonstrated commercial monetization of its pipeline. Persistent operating and net losses require continued investment before product economics can be proven, leaving results highly dependent on clinical and development progress.

Persistent Cash Burn

Sustained negative operating and free cash flow indicates that operations continue to consume capital rather than generate funding internally. The much larger TTM outflow increases the likelihood of ongoing external funding needs and makes financial planning less predictable.

Volatile Reported Balance Sheet

Sharp changes in reported equity and assets make the balance-sheet trajectory harder to assess and reduce confidence in the stability of the reported capital base. Combined with ongoing losses, this volatility can complicate financing and longer-term capital allocation decisions.

Reviva Pharmaceuticals Holdings News

RVPH FAQ

What was Reviva Pharmaceuticals Holdings’s price range in the past 12 months?
Reviva Pharmaceuticals Holdings lowest stock price was $0.26 and its highest was $15.42 in the past 12 months.
What is Reviva Pharmaceuticals Holdings’s market cap?
Reviva Pharmaceuticals Holdings’s market cap is $3.93M.
When is Reviva Pharmaceuticals Holdings’s upcoming earnings report date?
Reviva Pharmaceuticals Holdings’s next earnings report is estimated for Apr 05, 2027 (not yet confirmed), which is in 134 days.
How were Reviva Pharmaceuticals Holdings’s earnings last quarter?
Reviva Pharmaceuticals Holdings released its earnings results on Nov 13, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.12.
Is Reviva Pharmaceuticals Holdings overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Reviva Pharmaceuticals Holdings pay dividends?
Reviva Pharmaceuticals Holdings does not currently pay dividends.
What is Reviva Pharmaceuticals Holdings’s EPS estimate?
Reviva Pharmaceuticals Holdings’s EPS estimate is -0.19.
How many shares outstanding does Reviva Pharmaceuticals Holdings have?
Reviva Pharmaceuticals Holdings has 13,110,377 shares outstanding.
What happened to Reviva Pharmaceuticals Holdings’s price movement after its last earnings report?
Reviva Pharmaceuticals Holdings reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went down -9.021%.
Which hedge fund is a major shareholder of Reviva Pharmaceuticals Holdings?
Hedge funds hold Reviva Pharmaceuticals Holdings shares: the largest hedge-fund position in Reviva Pharmaceuticals Holdings is 70,129,617 shares, and hedge funds decreased their holdings by 780.8K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology